{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=19", "query": { "intervention": "Arm 1- Dose Escalation", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:28:09.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01207323", "title": "A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Tumors, Malignant" ], "interventions": [ { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-11-09", "completion_date": "2018-04-23", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 3, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207323" }, { "nct_id": "NCT04752774", "title": "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Spasticity" ], "interventions": [ { "name": "Corabotase", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dysport", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 240, "start_date": "2021-04-29", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 5, "location_summary": "Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more", "locations": [ { "city": "Downey", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Elkins Park", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752774" }, { "nct_id": "NCT00858377", "title": "A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Solid Tumors", "Tumors" ], "interventions": [ { "name": "Arm 1- Dose Escalation", "type": "DRUG" }, { "name": "Arm 1- Dose Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2009-08-10", "completion_date": "2019-04-03", "has_results": false, "last_update_posted_date": "2019-05-06", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858377" }, { "nct_id": "NCT00499902", "title": "Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Ischemic Stroke" ], "interventions": [ { "name": "alfimeprase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ARCA Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 7, "start_date": "2007-06", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2008-04-24", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 17, "location_summary": "Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499902" }, { "nct_id": "NCT00589875", "title": "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "High Grade Glioma" ], "interventions": [ { "name": "CAN-2409", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-03", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589875" }, { "nct_id": "NCT01129180", "title": "Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Prolymphocytic Leukemia", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Small Intestine Lymphoma", "T-cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "azacitidine", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "Correlative studies", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Pierluigi Porcu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2010-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-12-03", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129180" }, { "nct_id": "NCT03656627", "title": "Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Diseases", "Non-small Cell Lung Cancer", "Rheumatoid Arthritis", "Psoriasis", "Giant Cell Arteritis", "Polymyalgia Rheumatica", "Systemic Lupus Erythematosus", "Crohn Disease", "Multiple Sclerosis", "Ulcerative Colitis" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-06-27", "completion_date": "2021-03-18", "has_results": false, "last_update_posted_date": "2023-02-15", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 9, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656627" }, { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" }, { "nct_id": "NCT04990739", "title": "Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "MTB-9655", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MetaboMed Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-06-30", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990739" }, { "nct_id": "NCT02947100", "title": "Omega-3 Fatty Acids in Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "SCD-Omegatex™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robin E. Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "8 Years to 25 Years" }, "enrollment_count": 4, "start_date": "2018-01-25", "completion_date": "2018-10-15", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-15T14:28:09.892Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947100" } ] }